Michaelides S, Obeck H, Kechur D, Endres S, Kobold S. Migratory engineering of T cells for cancer therapy. Vaccines. 2022;10:1845.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellino S, La Salvia A, Cometa MF, Botta R. Cell-based medicinal products approved in the European Union: current evidence and perspectives. Front Pharmacol. 2023;14:1200808.

Article  PubMed  PubMed Central  Google Scholar 

Benmebarek M-R, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20:1283.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:22.

Article  PubMed  PubMed Central  Google Scholar 

Research C for BE and. FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. FDA. 2023 https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous. Accessed 27 May 2024.

Umut Ö, Gottschlich A, Endres S, Kobold S. CAR T cell therapy in solid tumors: a short review. Memo. 2021;14:143–9.

Article  PubMed  PubMed Central  Google Scholar 

Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15:2548–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xia A-L, Wang X-C, Lu Y-J, Lu X-J, Sun B. Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. Oncotarget. 2017;8:90521–31.

Article  PubMed  PubMed Central  Google Scholar 

Chen K, Wang S, Qi D, Ma P, Fang Y, Jiang N, et al. Clinical investigations of CAR-T cell therapy for solid tumors. Front Immunol. 2022;13: 896685.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schoenberg SO, Attenberger UI, Solomon SB, Weissleder R. Developing a roadmap for interventional oncology. Oncologist. 2018;23:1162–70.

Article  PubMed  PubMed Central  Google Scholar 

Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yaromina A, Krause M, Baumann M. Individualization of cancer treatment from radiotherapy perspective. Mol Oncol. 2012;6:211–21.

Article  PubMed  PubMed Central  Google Scholar 

Knavel EM, Brace CL. Tumor ablation: common modalities and general practices. Tech Vasc Interv Radiol. 2013;16:192–200.

Article  PubMed  PubMed Central  Google Scholar 

Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A, et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015;16:1193–224.

Article  PubMed  Google Scholar 

Ricke J, Westphalen CB, Seidensticker M. Therapeutic concepts for oligometastatic gastrointestinal tumours. Visc Med. 2020;36:359–63.

Article  PubMed  PubMed Central  Google Scholar 

Li M, Xue S-L, Tang X, Xu J, Chen S, Han Y, et al. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. Sci Rep. 2022;12:378.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan Z, Zhang H, Cao J, Zhang C, Liu H, Huang H, et al. Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunol. 2021;12: 611366.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Z, Ali M, Kai Z, Wang Y, Wang C. HIPEC with CRS versus cytoreductive surgery (CRS) for the gastric cancer metastasis to peritoneum. Clin Transl Oncol. 2023;25:1011–6.

Article  CAS  PubMed  Google Scholar 

Sagnella SM, White AL, Yeo D, Saxena P, van Zandwijk N, Rasko JEJ. Locoregional delivery of CAR-T cells in the clinic. Pharmacol Res. 2022;182: 106329.

Article  CAS  PubMed  Google Scholar 

Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249–79.

Article  CAS  PubMed  Google Scholar 

Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25:11–7.

Article  PubMed  Google Scholar 

Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, et al. Advances in cancer immunotherapy 2019: latest trends. J Exp Clin Cancer Res. 2019;38:268.

Article  PubMed  PubMed Central  Google Scholar 

Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044–60.

Article  PubMed  PubMed Central  Google Scholar 

Stock S, Kluever A-K, Endres S, Kobold S. Enhanced chimeric antigenr eceptor T cell therapy through co-application of synergistic combination partners. Biomedicines. 2022;10:307.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, et al. Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol Res. 2016;4:744–54.

Article  CAS  PubMed  Google Scholar 

Leuchte K, Staib E, Thelen M, Gödel P, Lechner A, Zentis P, et al. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70:893–907.

Article  CAS  PubMed  Google Scholar 

Sha CM, Lehrer EJ, Hwang C, Trifiletti DM, Mackley HB, Drabick JJ, et al. Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis. Radiother Oncol. 2020;151:141–8.

Article  CAS  PubMed  Google Scholar 

Choi B, Kim D-H. Multifunctional nanocarriers-mediated synergistic combination of immune checkpoint inhibitor cancer immunotherapy and interventional oncology therapy. Adv Nanobiomed Res. 2021;1:2100010.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mooradian M, Fintelmann FJ, Kaufman HE, Mino-Kenudson M, Barth JL, Lawless A, et al. The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma. J Clin Oncol. 2021;39:9538–9538.

Article  Google Scholar 

Zhao J, Wen X, Tian L, Li T, Xu C, Wen X, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun. 2019;10:899.